Trade ProShares Ultra Nasdaq Biotechnology - BIB
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®.The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. This ETF offers 2x daily long leverage to the broad-based NASDAQ Biotechnology Index, making it a powerful tool for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies. Investors should note that BIB’s leverage resets on a daily basis, which results in compounding of returns when held for multiple periods.Latest shares articles

TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
3 hours ago

Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
5 hours ago

Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
7 hours ago

GameStop stock forecast: debt exchange, Q2 profit
GameStop is a US video-game retailer. In Q2 fiscal 2026, net sales fell to $790.2m, while operating income rose to $160.2m. Explore third-party GME price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:06, 7 October 2026